SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Tag: Price Transparency

Insurers must be forced to justify huge annual increases | Daily Mail Online

Insurers must be forced to justify huge annual increases | Daily Mail Online

Pensioners are the worst-hit because they are less likely to look for deals online. The calls for insurers to be forced to justify to customers why they have hiked their premium come after a Money Mail investigation found long-standing customers are being over-charged by up to £1,000, while insurers offer new customers loss-making introductory deals. […]

La. Politics: Lawmakers looking into prescription drug pricing | Daily Comet

La. Politics: Lawmakers looking into prescription drug pricing | Daily Comet

A set of bills moving through the state Legislature’s ongoing regular session would create new layers of disclosure in regard to prescription drug pricing in Louisiana. The policy push has caught the attention of the Pharmaceutical Research and Manufacturers of America, which represents companies that research, develop and market medicines. They’re also companies that are […]

New price for muscular dystrophy drug draws criticism | CNBC

New price for muscular dystrophy drug draws criticism | CNBC

Deflazacort wasn’t approved in the U.S., so McSherry and a number of other families of kids with Duchenne imported the drug from overseas. She says it cost about $1,200 a year out of pocket. Monday, deflazacort got a new price tag: $35,000 a year for a patient in the U.S. weighing 25 kilograms, or about […]

Holiday prices can soar by £3,000 in just one day | Daily Mail Online

Holiday prices can soar by £3,000 in just one day | Daily Mail Online

  Study exposes inconsistencies in travel industry over the cost of family deals The price of a trip to Florida apparently soared by £3,370 in just a single day  Research finds families struggle to know if their quote is fair    We’re all wary of holiday rip-offs, knowing prices can soar if you book late or […]

Big Pharma Losing Leverage as Payers Raise Pressure on Price | Bloomberg

Big Pharma Losing Leverage as Payers Raise Pressure on Price | Bloomberg

The world’s biggest drugmakers don’t have the muscle they used to have. Pharmaceutical and biotechnology giants are finding it more difficult to charge high prices for a range of medications, their latest quarterly results show. That’s raising the pressure to pump up sales volumes and find lucrative new treatments for niche markets. “You had an […]

Fair pricing or pricing for profit? | CMAJ News

Fair pricing or pricing for profit? | CMAJ News

If you had $500 000, would you provide drugs to one person who has a rare disease for a year, cure ten people of hepatitis C, or treat 500 with diabetes? This sort of question is plaguing cash-strapped public pharmacare programs in Canada. What is fair pricing? It’s a question making headlines and prompting debate, such […]

Amgen: The Bear Case From a Bull | Madison.com

Amgen: The Bear Case From a Bull | Madison.com

Long story short, the recent introduction of Inflectra, Pfizer’s (NYSE: PFE) biosimilar to Johnson & Johnson’s (NYSE: JNJ) Remicade, could negatively affect the pricing power for anti-inflammatory drugs as a whole. After all, Pfizer has already announced that Inflectra will initially be sold at a 15% discount to the wholesaler acquisition cost of J&J’s Remicade, which may spur a round of deeper […]

Four Areas Your Yearly Pricing Review Might Be Missing | HealthLeaders Media

Four Areas Your Yearly Pricing Review Might Be Missing | HealthLeaders Media

Hospitals and health systems face a number of important decisions when determining how to price services and delivery of care. Your ability to regularly review and align your pricing strategy has become even more significant in the face of mergers and acquisitions, software conversions, and healthcare consumers responsible for increasing deductibles. Incorrectly set prices can […]

Better Buy: Amgen Inc. vs. Biogen | The Motley Fool

Better Buy: Amgen Inc. vs. Biogen | The Motley Fool

Valeant Pharmaceuticals (NYSE:VRX) has been more bullish about the prospects for brodalumab, now branded as Siliq, than anyone. Amgen bailed out on the psoriasis drug after late-stage study results raised concerns about Siliq causing patients to have suicidal thoughts. AstraZeneca publicly stated that it would move forward without Amgen, but soon afterward began shopping the drug […]

Marathon Pharmaceutical resigns from industry lobbying group PhRMA following pricing controversy | Healthcare Finance

Marathon Pharmaceutical resigns from industry lobbying group PhRMA following pricing controversy | Healthcare Finance

With the sale of its controversial rare-disease drug finalized, Marathon Pharmaceuticals has taken the unusual step of resigning from the powerful industry lobbying group PhRMA.| Marathon had been a member of the Pharmaceutical Research and Manufacturers of America, and Marathon’s CEO, Jeffrey Aronin, had held a position on the board. The news of Marathon’s resignation […]